Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
March 31, 2025
March 31, 2025
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder
February 25, 2025
February 25, 2025
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
January 29, 2025
January 29, 2025
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
November 6, 2024
November 6, 2024
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
November 4, 2024
New Treatment Insights into Switching to UZEDY® from Perseris®
September 23, 2024
September 23, 2024
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
MedinCell’s partner Teva announces successful launch of UZEDY™
